About Abiraterone Acetate API
Therapeutic Category Oncology
CAS Number
154229-18-2
API Technology
Steroids
Dose Form
Tablets
Dr Reddy's Development Status
Available
Available Regulatory Filing
USDMF, Brazil DMF, EUDMF, Korea DMF, Russia DMF
Mechanism of Action
Abiraterone is an orally active inhibitor of the steroidal enzyme CYP17A1 (17 alpha-hydroxylase/C17,20 lyase). It inhibits CYP17A1 in a selective and irreversible manner via covalent binding mechanism.
Indication
ZYTIGA is a CYP17 inhibitor indicated in combination with prednisone for the treatment of patients with
- Metastatic castration-resistant prostate cancer (CRPC).
- Metastatic high-risk castration-sensitive prostate cancer (CSPC)
Request for Quotation
Get in touch with us by filling out the form below. Our team will reach out to you shortly!
Related APIs
Adagrasib
Oncology
Fruquintinib
Oncology
Tucatinib
Oncology
Ripretinib
Oncology
Cabozantinib Hydrochloride
Oncology
Cabozantinib S-Malate
Oncology
Carfilzomib
Oncology
Deucravacitinib
Oncology
Acalabrutinib
Oncology
Capivasertib
Oncology
Lenvatinib Mesylate (Form C and MIBK Solvate)
Oncology
Abiraterone Acetate
Oncology
Apalutamide (Amorphous & Form B)
Oncology
Zoledronic Acid
Oncology
Azacitidine
Oncology
Bendamustine Hydrochloride
Oncology
Relugolix
Oncology
Bortezomib
Oncology
Cabazitaxel
Oncology
Capecitabine
Oncology
Pomalidomide
Oncology
Pemetrexed Disodium Heptahydrate
Oncology
Pazopanib
Oncology
Palbociclib
Oncology
Dasatinib (Monohydrate)
Oncology
Olaparib (Form A)
Oncology
Decitabine
Oncology
Nilotinib Hydrochloride Monohydrate (Form B)
Oncology
Midostaurin (Amorphous and Form II)
Oncology
Enzalutamide (Crystalline & Premix)
Oncology
Eribulin Mesylate
Oncology
Gemcitabine Hydrochloride
Oncology
Lenalidomide (Form A)
Oncology
Lomustine
Oncology
